Status:
COMPLETED
Erlotinib (Tarceva (Trademark), OSI-774) in Treating Patients With Advanced Non-Small Cell Lung Cancer
Lead Sponsor:
OSI Pharmaceuticals
Conditions:
Advanced Non Small Cell Lung Cancer
Failed Prior Chemotherapy
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine if erlotinib will improve disease at doses that produce its characteristic rash in patients with advanced Non-Small Cell Lung Cancer.
Detailed Description
Only patients with 0 to 1 performance status on the ECOG scale are eligible.
Eligibility Criteria
Inclusion
- Confirmed diagnosis of Stage IIIB or IV non-small cell lung cancer (histological or cytological).
- Received prior chemotherapy treatment for advanced, metastatic non-small cell lung cancer.
- Measurable disease per RECIST criteria.
- Adequate bone marrow, hepatic and renal function.
Exclusion
- Breast cancer or skin cancer at any time in the past or any other cancer in the past 5 years.
- Brain metastases that are unstable, require steroids, are life-threatening or required radiation in the last 28 days.
- Known hypersensitivity to minocycline.
- History of serious cardiac disease that is not controlled.
- Serious eye conditions.
- Prior treatment with inhibitors of EGFR of any kind.
Key Trial Info
Start Date :
November 5 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 14 2007
Estimated Enrollment :
43 Patients enrolled
Trial Details
Trial ID
NCT00072631
Start Date
November 5 2003
End Date
March 14 2007
Last Update
February 8 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institute for Drug Development Cancer Therapy and Research Center
San Antonio, Texas, United States, 78229